Efficacy, safety and prognostic features of resected colon carcinoma treated in "real world" practice: A retrospective cohort-study

Journal of B.U.ON.

Volumn 16, Issue 2, 2011, Pages 257-264

  Dane, Faysal ^a   Akif Ozturk, M ^a   Gumus, M ^b   Guven, A ^a   Aliustaoglu, M ^c   Cabuk, D ^a   Teomete, M ^a   Basaran, G ^a   Fulden Yumuk, P ^a   Serdar Turhal, N ^a  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b DR LUTFI KIRDAR KARTAL EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^c HAYDARPASA NUMUNE EDUCATION AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Adjuvant treatment; Colon cancer; Fluorouracil; Oxaliplatin; Real world

Indexed keywords

FLUOROURACIL; OXALIPLATIN;

ADULT; AGED; ANOREXIA; ARTICLE; ASTHENIA; CANCER ADJUVANT THERAPY; CANCER STAGING; COLON CARCINOMA; CONSTIPATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEART DISEASE; HEMATOLOGIC DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; NEUROPATHY; PAIN; PROGNOSIS; RETROSPECTIVE STUDY; SIDE EFFECT; STOMATITIS; THROMBOSIS; THYROID FUNCTION; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COLONIC NEOPLASMS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 79960228637     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Jemal A, Siegal R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. American Cancer Society: Cancer Statistics of 2008 [http://www.cancer. org/downloads/STT/2008CAFFfinalsecured.pdf]
3. Wolpin BM, Meyerhardt JA, Mamon HJ, Mayer RJ. Adjuvant treatment of colorectal cancer. CA Cancer J Clin 2007; 57: 168-185. (Pubitemid 46798625)
4. Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP. American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 2000; 88: 1739-1757. (Pubitemid 30183160)
5. Krasna MJ, Flancbaum L, Cody RP, Shneibaum S, Ben Ari G. Vascular and neural invasion in colorectal carcinoma. Incidence and prognostic significance. Cancer 1988; 61: 1018-1023.
6. Wolmark N, Fisher B, Wieand HS et al. The prognostic significance of preoperative carcinoembryonic antigen levels in colorectal cancer. Results from NSABP (National Surgical Adjuvant Breast and Bowel Project) clinical trials. Ann Surg 1984; 199: 375-382. (Pubitemid 14139870)
7. Moertel CG, Fleming TR, McDonald JS et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol 1995; 13: 2936-2943.
8. Watanabe T, Wu TT, Catalano PJ et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001; 344: 1196-1206. (Pubitemid 32319494)
9. Popat S, Houlston RS. A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur J Cancer 2005; 41: 2060-2070. (Pubitemid 41337947)
10. Swanson RS, Compton CC, Stewart AK, Bland KI. The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol 2003; 10: 65-71.
11. National Comprehensive Cancer Network (NCCN) Colon cancer treatment guideline [http://www.nccn.org/professionals/physician-gls/PDF/colon.pdf]
12. Wolmark N, Rockette H, Fisher B et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993; 11: 1879-1887. (Pubitemid 23304611)
13. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International multicentre pooled analysis of colon cancer trials (IMPACT) investigators. Lancet 1995; 345: 939-944.
14. Haller DG, Catalano PJ, Macdonald JS et al. Phase III study of fluorouracil, leucovorin and levamisole in high risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 2005; 23: 8671-8678. (Pubitemid 46211510)
15. Twelves C, Wong A, Nowacki MP et al. Capacitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696-2704. (Pubitemid 41007824)
16. Lembersky BC, Wieand HS, Petrelli NJ et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 2006; 24: 2059-2064. (Pubitemid 46622115)
17. Andre T, Boni C, Mounedji-Boudiaf et al. Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators: Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351.
18. Kuebler JP, Wieand HS, O'Connell MJ et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007; 25: 2198-2204. (Pubitemid 46954643)
19. Common Toxicity Criteria version 2.0 [http://ctep.cancer.gov/ protocolDevelopment/electronicapplications/docs/ctcv20-4-30-992.pdf]
20. O'Connell MJ, Mailliard JA, Kahn MJ et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15: 246-250. (Pubitemid 27020580)
21. de Gramont A, Boni C, Navarro M et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of 6 years. J Clin Oncol 2007; 25: 4007 (abstr).
22. Gill S, Loprinzi CL, Sargent DJ et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer who benefits and by how much? J Clin Oncol 2004; 22: 1797-1806.
23. Sundararajan V, Mitra N, Jacobson JS, Grann VR, Heitjan DF, Neugut AI. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med 2002; 136: 349-357. (Pubitemid 34183993)
24. Sargent DJ, Goldberg RM, Jacobson SD et al. Apooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001; 345: 1091-1097.
25. Jessup JM, Stewart A, Greene FL, Minsky BD. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA 2005; 294: 2703-2711. (Pubitemid 41770099)
26. Bostankolu O, Ozturk B, Coskun U, Buyukberber S, Benekli M. Cancer Chemotherapy in Elderly Patients. Intern J Hematol Oncol 2008; 18: 186-192.
27. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004; 96: 1420-1425. (Pubitemid 39429665)
28. Lothe RA, Peltomaki P, Meling GI et al. Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res 1993; 53: 5849-5852. (Pubitemid 24006146)
29. Locker GY, Hamilton S, Harris J et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24: 5313-5327.
30. Lindmark G, Bergström R, Pahlman L, Glimelius B. The association of preoperative serum tumour markers with Dukes' stage and survival in colorectal cancer. Br J Cancer 1995; 71: 1090-1094.